These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1230 related items for PubMed ID: 8832108

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew FY, Colombo MP.
    Cancer Res; 2002 Aug 01; 62(15):4390-7. PubMed ID: 12154045
    [Abstract] [Full Text] [Related]

  • 3. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
    Kawamura K, Bahar R, Natsume W, Sakiyama S, Tagawa M.
    Cancer Gene Ther; 2002 Jan 01; 9(1):109-15. PubMed ID: 11916240
    [Abstract] [Full Text] [Related]

  • 4. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM, Mahtabifard A, Yamada R, Crystal RG, Korst RJ.
    Clin Cancer Res; 2002 Nov 01; 8(11):3561-9. PubMed ID: 12429647
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.
    Adris S, Chuluyan E, Bravo A, Berenstein M, Klein S, Jasnis M, Carbone C, Chernajovsky Y, Podhajcer OL.
    Cancer Res; 2000 Dec 01; 60(23):6696-703. PubMed ID: 11118055
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells.
    Tasaki K, Yoshida Y, Maeda T, Miyauchi M, Kawamura K, Takenaga K, Yamamoto H, Kouzu T, Asano T, Ochiai T, Sakiyama S, Tagawa M.
    Cancer Gene Ther; 2000 Feb 01; 7(2):247-54. PubMed ID: 10770633
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
    Ohashi M, Kobayashi A, Hara H, Miura Y, Yoshida K, Kushida M, Ikarashi Y, Mandai M, Kitajima M, Yoshida T, Aoki K.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2208-15. PubMed ID: 16609036
    [Abstract] [Full Text] [Related]

  • 11. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response.
    Adris S, Klein S, Jasnis M, Chuluyan E, Ledda M, Bravo A, Carbone C, Chernajovsky Y, Podhajcer O.
    Gene Ther; 1999 Oct 01; 6(10):1705-12. PubMed ID: 10516719
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of peritoneal dissemination of murine colon carcinoma cells by administrating retrovirus harboring IL-2 gene.
    Gunji Y, Tasaki K, Tagawa M, Matsubara H, Takenaga K, Suzuki T, Asano T, Ochiai T, Isono K, Sakiyama S.
    Cancer Gene Ther; 1998 Oct 01; 5(6):339-43. PubMed ID: 9917087
    [Abstract] [Full Text] [Related]

  • 13. Transduction of murine colon carcinoma cells with interleukin-15 gene induces antitumor effects in immunocompetent and immunocompromised hosts.
    Tasaki K, Yoshida Y, Miyauchi M, Maeda T, Takenaga K, Kouzu T, Asano T, Ochiai T, Sakiyamna S, Tagawa M.
    Cancer Gene Ther; 2000 Feb 01; 7(2):255-61. PubMed ID: 10770634
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E, Aruga A, Arca MJ, Lee WM, Yang NS, Smith JW, Chang AE.
    Cancer Gene Ther; 1997 Feb 01; 4(3):157-66. PubMed ID: 9171934
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential.
    Mullen CA, Coale MM, Levy AT, Stetler-Stevenson WG, Liotta LA, Brandt S, Blaese RM.
    Cancer Res; 1992 Nov 01; 52(21):6020-4. PubMed ID: 1394227
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.